The authors note that currently, a Phase II trial examining an IDH1 inhibitor IDH305 in grade II or III glioma with any mIDH1 subtype (NCT02977689, ClinicalTrials.gov), as well as a Phase I trial examining an IDH1 peptide vaccine in grade III and IV glioma with mIDH1 R132H subtype (NCT02454634, ClinicalTrials.gov), are currently recruiting. The gene discussed is IDH1; the disease is central nervous system cancer.